LONDON — Emma Walmsley has been named to succeed Sir Andrew Witty as chief executive officer of GlaxoSmithKline plc. The drug maker said Tuesday that Walmsley, CEO of GSK Consumer Healthcare, is slated to take the reins from Witty when he retires on March 31, 2017. Plans call for her to become a member of
WARREN, N.J. — One of the world’s largest consumer health care companies celebrated the grand opening of its new state-of-the-art headquarters here earlier this month with company leaders and federal, state and local dignitaries. GlaxoSmithKline Consumer Healthcare — known for such brands as Sensodyne, Theraflu, Excedrin, Nicorette and NicoDermCQ, Flonase, and TUMS — held the
LONDON — Sir Andrew Witty, chief executive officer of GlaxoSmithKline plc, plans to retire from the company next year. GSK announced Witty’s retirement Thursday in releasing its 2015 annual report to shareholders. Plans call for Witty to step down from the CEO post on March 31, 2017. The board of directors plans to conduct a
WARREN, N.J. — GSK Consumer Healthcare has launched Children’s Flonase, a pediatric version of its now over-the-counter allergy nasal spray. GlaxoSmithKline said Tuesday that Children’s Flonase is approved to offer non-drowsy relief of allergy symptoms including runny nose, sneezing, itchy nose and congestion, as well as itchy, watery eyes. Available in stores nationwide in the
HERTFORDSHIRE, England, and PITTSBURGH — Mylan N.V. has tabbed GlaxoSmithKline Consumer Healthcare veteran Ranjan Ray Chaudhuri to serve as global commercial lead of Mylan’s over-the-counter business. Chaudhuri will report to Rajiv Malik, president of Mylan. “The opportunity to build upon Mylan’s one-of-a-kind global platform and contribute to the organization’s ongoing evolution is tremendously exciting to
PARSIPPANY, N.J. — Procter & Gamble veteran Dennis Curran has joined GlaxoSmithKline Consumer Healthcare as U.S. vice president of sales and chief customer officer. GSK Consumer Healthcare said Friday that, in the role, Curran will be responsible for driving the company-customer relationship with retail partners and leading the sales organization to deliver an optimum shopper
NEW YORK — Pfizer Inc. plans to buy GlaxoSmithKline’s quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for about $130 million. (NYSE: PFE) today announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130 million (€115 million). Pfizer
